Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
37
CGON Quote, Financials, Valuation and Earnings
Last price:
$43.29
Seasonality move
:
-29.45%
Day range:
$43.02 - $46.01
52-week range:
$14.80 - $46.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,520.18x
P/B ratio:
4.80x
Volume:
745.5K
Avg. volume:
914.6K
1-year change:
29.02%
Market cap:
$3.3B
Revenue:
$1.1M
EPS (TTM):
-$1.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CGON
CG Oncology, Inc.
|
$72.6K | -$0.55 | 24.28% | -41.88% | $70.77 |
|
CCCC
C4 Therapeutics, Inc.
|
$6.3M | -$0.39 | 7.69% | -25.47% | $11.86 |
|
DNLI
Denali Therapeutics, Inc.
|
$1M | -$0.76 | 559.6% | -13.28% | $32.29 |
|
GERN
Geron Corp.
|
$53.3M | -$0.04 | 7.03% | -8.38% | $3.60 |
|
IDYA
IDEAYA Biosciences, Inc.
|
$60M | -$0.55 | -15.05% | -37.84% | $49.47 |
|
NTLA
Intellia Therapeutics, Inc.
|
$14.1M | -$0.98 | -5.94% | -24.06% | $24.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CGON
CG Oncology, Inc.
|
$43.30 | $70.77 | $3.3B | -- | $0.00 | 0% | 1,520.18x |
|
CCCC
C4 Therapeutics, Inc.
|
$2.67 | $11.86 | $258.8M | -- | $0.00 | 0% | 6.32x |
|
DNLI
Denali Therapeutics, Inc.
|
$19.96 | $32.29 | $2.9B | -- | $0.00 | 0% | 6.62x |
|
GERN
Geron Corp.
|
$1.31 | $3.60 | $836.2M | -- | $0.00 | 0% | 4.76x |
|
IDYA
IDEAYA Biosciences, Inc.
|
$35.87 | $49.47 | $3.1B | -- | $0.00 | 0% | 14.77x |
|
NTLA
Intellia Therapeutics, Inc.
|
$9.61 | $24.85 | $1.1B | -- | $0.00 | 0% | 17.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CGON
CG Oncology, Inc.
|
1.04% | 1.903 | 0.24% | 22.30x |
|
CCCC
C4 Therapeutics, Inc.
|
28.47% | 3.112 | 37.33% | 5.52x |
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 1.220 | 2.09% | 9.43x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.755 | 1.14% | 12.20x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 3.323 | 4.9% | 5.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CGON
CG Oncology, Inc.
|
-$327K | -$51.1M | -22.66% | -22.73% | -3068.97% | -$39M |
|
CCCC
C4 Therapeutics, Inc.
|
$9.2M | -$23.7M | -45.67% | -60.62% | -210.86% | -$31.6M |
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
CG Oncology, Inc. vs. Competitors
-
Which has Higher Returns CGON or CCCC?
C4 Therapeutics, Inc. has a net margin of -2629.53% compared to CG Oncology, Inc.'s net margin of -286.43%. CG Oncology, Inc.'s return on equity of -22.73% beat C4 Therapeutics, Inc.'s return on equity of -60.62%.
Company Gross Margin Earnings Per Share Invested Capital CGONCG Oncology, Inc.-19.63% -$0.57 $694.9M CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M -
What do Analysts Say About CGON or CCCC?
CG Oncology, Inc. has a consensus price target of $70.77, signalling upside risk potential of 63.44%. On the other hand C4 Therapeutics, Inc. has an analysts' consensus of $11.86 which suggests that it could grow by 344.09%. Given that C4 Therapeutics, Inc. has higher upside potential than CG Oncology, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than CG Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGONCG Oncology, Inc.10 0 0 CCCCC4 Therapeutics, Inc.7 0 0 -
Is CGON or CCCC More Risky?
CG Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison C4 Therapeutics, Inc. has a beta of 2.874, suggesting its more volatile than the S&P 500 by 187.406%.
-
Which is a Better Dividend Stock CGON or CCCC?
CG Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. C4 Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CG Oncology, Inc. pays -- of its earnings as a dividend. C4 Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGON or CCCC?
CG Oncology, Inc. quarterly revenues are $1.7M, which are smaller than C4 Therapeutics, Inc. quarterly revenues of $11.2M. CG Oncology, Inc.'s net income of -$43.8M is lower than C4 Therapeutics, Inc.'s net income of -$32.2M. Notably, CG Oncology, Inc.'s price-to-earnings ratio is -- while C4 Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CG Oncology, Inc. is 1,520.18x versus 6.32x for C4 Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGONCG Oncology, Inc.1,520.18x -- $1.7M -$43.8M CCCCC4 Therapeutics, Inc.6.32x -- $11.2M -$32.2M
-
Which has Higher Returns CGON or DNLI?
Denali Therapeutics, Inc. has a net margin of -2629.53% compared to CG Oncology, Inc.'s net margin of --. CG Oncology, Inc.'s return on equity of -22.73% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.
Company Gross Margin Earnings Per Share Invested Capital CGONCG Oncology, Inc.-19.63% -$0.57 $694.9M DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M -
What do Analysts Say About CGON or DNLI?
CG Oncology, Inc. has a consensus price target of $70.77, signalling upside risk potential of 63.44%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.29 which suggests that it could grow by 61.39%. Given that CG Oncology, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe CG Oncology, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGONCG Oncology, Inc.10 0 0 DNLIDenali Therapeutics, Inc.17 0 0 -
Is CGON or DNLI More Risky?
CG Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.
-
Which is a Better Dividend Stock CGON or DNLI?
CG Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CG Oncology, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGON or DNLI?
CG Oncology, Inc. quarterly revenues are $1.7M, which are larger than Denali Therapeutics, Inc. quarterly revenues of --. CG Oncology, Inc.'s net income of -$43.8M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, CG Oncology, Inc.'s price-to-earnings ratio is -- while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CG Oncology, Inc. is 1,520.18x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGONCG Oncology, Inc.1,520.18x -- $1.7M -$43.8M DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M
-
Which has Higher Returns CGON or GERN?
Geron Corp. has a net margin of -2629.53% compared to CG Oncology, Inc.'s net margin of -39.02%. CG Oncology, Inc.'s return on equity of -22.73% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital CGONCG Oncology, Inc.-19.63% -$0.57 $694.9M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About CGON or GERN?
CG Oncology, Inc. has a consensus price target of $70.77, signalling upside risk potential of 63.44%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 174.81%. Given that Geron Corp. has higher upside potential than CG Oncology, Inc., analysts believe Geron Corp. is more attractive than CG Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGONCG Oncology, Inc.10 0 0 GERNGeron Corp.3 1 1 -
Is CGON or GERN More Risky?
CG Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock CGON or GERN?
CG Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CG Oncology, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGON or GERN?
CG Oncology, Inc. quarterly revenues are $1.7M, which are smaller than Geron Corp. quarterly revenues of $47.2M. CG Oncology, Inc.'s net income of -$43.8M is lower than Geron Corp.'s net income of -$18.4M. Notably, CG Oncology, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CG Oncology, Inc. is 1,520.18x versus 4.76x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGONCG Oncology, Inc.1,520.18x -- $1.7M -$43.8M GERNGeron Corp.4.76x -- $47.2M -$18.4M
-
Which has Higher Returns CGON or IDYA?
IDEAYA Biosciences, Inc. has a net margin of -2629.53% compared to CG Oncology, Inc.'s net margin of 57.38%. CG Oncology, Inc.'s return on equity of -22.73% beat IDEAYA Biosciences, Inc.'s return on equity of -15.12%.
Company Gross Margin Earnings Per Share Invested Capital CGONCG Oncology, Inc.-19.63% -$0.57 $694.9M IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B -
What do Analysts Say About CGON or IDYA?
CG Oncology, Inc. has a consensus price target of $70.77, signalling upside risk potential of 63.44%. On the other hand IDEAYA Biosciences, Inc. has an analysts' consensus of $49.47 which suggests that it could grow by 37.92%. Given that CG Oncology, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe CG Oncology, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGONCG Oncology, Inc.10 0 0 IDYAIDEAYA Biosciences, Inc.13 2 0 -
Is CGON or IDYA More Risky?
CG Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IDEAYA Biosciences, Inc. has a beta of 0.040, suggesting its less volatile than the S&P 500 by 96.023%.
-
Which is a Better Dividend Stock CGON or IDYA?
CG Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEAYA Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CG Oncology, Inc. pays -- of its earnings as a dividend. IDEAYA Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGON or IDYA?
CG Oncology, Inc. quarterly revenues are $1.7M, which are smaller than IDEAYA Biosciences, Inc. quarterly revenues of $207.8M. CG Oncology, Inc.'s net income of -$43.8M is lower than IDEAYA Biosciences, Inc.'s net income of $119.2M. Notably, CG Oncology, Inc.'s price-to-earnings ratio is -- while IDEAYA Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CG Oncology, Inc. is 1,520.18x versus 14.77x for IDEAYA Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGONCG Oncology, Inc.1,520.18x -- $1.7M -$43.8M IDYAIDEAYA Biosciences, Inc.14.77x -- $207.8M $119.2M
-
Which has Higher Returns CGON or NTLA?
Intellia Therapeutics, Inc. has a net margin of -2629.53% compared to CG Oncology, Inc.'s net margin of -735.19%. CG Oncology, Inc.'s return on equity of -22.73% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital CGONCG Oncology, Inc.-19.63% -$0.57 $694.9M NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About CGON or NTLA?
CG Oncology, Inc. has a consensus price target of $70.77, signalling upside risk potential of 63.44%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 133.42%. Given that Intellia Therapeutics, Inc. has higher upside potential than CG Oncology, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than CG Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGONCG Oncology, Inc.10 0 0 NTLAIntellia Therapeutics, Inc.10 11 1 -
Is CGON or NTLA More Risky?
CG Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.
-
Which is a Better Dividend Stock CGON or NTLA?
CG Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CG Oncology, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGON or NTLA?
CG Oncology, Inc. quarterly revenues are $1.7M, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. CG Oncology, Inc.'s net income of -$43.8M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, CG Oncology, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CG Oncology, Inc. is 1,520.18x versus 17.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGONCG Oncology, Inc.1,520.18x -- $1.7M -$43.8M NTLAIntellia Therapeutics, Inc.17.51x -- $13.8M -$101.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 48.08% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 5.53% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.72% over the past day.
